A síntese e o perfil anti-inflamatório e analgésico dos novos agentes isocromanilacetilarilidrazônicos são descritos neste artigo. A rota sintética utilizada neste trabalho explora como passo chave para a construção de um anel heterocíclico de seis membros, a ciclização catalisada por um ácido de Lewis, que representa uma modificação da reação de Friedel-Crafts. Estes novos derivados (3) são obtidos em ca. de 85% de rendimento, a partir do safrol (4) utilizado como produto natural abundante, isolado do óleo de Sassafrás. A análise dos espectros de RMN destes novos derivados indica a natureza diastereoisomérica a nível da ligação C=N, na razão de 70:30, onde a maior contribuição é relativa ao isômero (E). Os resultados obtidos da avaliação farmacológica de (3) no teste do edema de pata de rato induzido por carragenina e no teste de contorções abdominais induzidas pelo ácido acético, indicam a natureza farmacofórica da unidade acilidrazona para a atividade analgésica observada nesta série. O papel dos substituintes na sub-unidade arila na atividade farmacológica parece indicar que a presença de grupos hidrofóbicos podem elevar o perfil analgésico. Estes novos derivados isocromanilacetilarilidrazônicos (3) representam nova classe de agentes analgésicos não-convencionais.
Introduction
Several cell mediators have been proposed to play a role in inflammatory processes and hyperalgesia, since these compounds caused a decrease in pain thresholds 1 . The prostaglandins PGs, in particular, have been suggested to play a major role in the pathogenesis of inflammation and in the production of inflammatory pain [2] [3] [4] . The recent disclosure of two distinct forms of cyclooxygenase (COX, prostaglandin-H synthase or PGHS) 5 indicated new directions for therapeutic approaches to inflammatory diseases 6 , confirming the role of icosanoids, produced by the COX enzyme which catalyzes the first two steps in the biosynthesis of PGs, producing the prostaglandin endoperoxide G2 and H2, precursors of all PGs. COX is the site of action of non-steroidal anti-inflammatory agents (NSAIS), and it is accepted that this is the basis of the anti-inflammatory action of these drugs 7 . The role of a second enzymatic pathway, namely 5-lipooxygenase (5-LO) in inflammation is also well known 8 . From arachidonic acid (AA), this enzyme produces the leucotrienes (LTs) which present chemotactil and bronco-constriction properties, also playing an important role in some chronic inflammatory diseases 9 .
In an effort to develop new synthetic bioactive compounds, as part of a research program aiming at the synthesis and pharmacological evaluation of new non-addictive analgesic and anti-inflammatory agents [10] [11] [12] [13] [14] [15] [16] [17] , we have previously described the synthesis and the anti-edematogenic properties of the isochromanyl acid derivatives (1) 16 . These compounds showed significant anti-inflammatory and analgesic activity, reducing the edema in the carrageenan induced the rat paw test with a dose of 25 mg/kg, and in reducing the number of constrictions in the acetic acid solution-induced test in mice with the same dose p.o. A second series of compounds, belonging to the acylhydrazone pyrazolic derivatives (2) 18 was also synthesized and pharmacologically evaluated for analgesic properties. These derivatives presented powerful activity in the mouse abdominal constrictions test induced by acetic acid 11 . The most potent compound of this series (2a, W=N(CH3)2) exhibited eleven times the analgesic activity of dipyrone in the same test at equimolar doses (ED50 = 15.8 mg/kg; P = 0.05). These results led us to identify compound (3) as an attractive new target in the search for new anti-inflammatory and analgesic compounds. This new class of derivatives was designed as a structural hybrid of both (1) and (2), previously synthesized and elected as 'lead compounds', as shown in Scheme 1.
In this paper we describe the synthesis and pharmacological profile of these new isochromanylacetylaryl hydrazone derivatives (3), using safrole (4), an abundant natural Brazilian product available from Sassafras oil (Ocotea pretiosa Mer., Lauraceae), as the synthetic starting material 19 .
Experimental

Chemistry
Melting points were determined with a hot-plate apparatus and were not corrected. Infrared (IR) spectra were obtained with a Perkin-Elmer 1600-FT spectrometer using potassium bromide pellets. Nuclear magnetic resonance (   1   H-NMR and   13 C-NMR) spectra were recorded in deuterochloroform containing ca. 1% TMS as an internal standard with a Bruker AC-200 FT at 200 MHz ( 1 H) and 50.3 MHz ( 13 C). Chemical shifts are expressed in ppm (δ) relative to TMS (= 0 ppm). Splitting patterns are as follows: s, singlet; d, doublet; t, triplet; q, quartet; m, multiplet; br, broad. The mass spectra were obtained with a GC/VG Micromass 12 at 70 eV. The progress of all reactions was monitored by thin layer chromatography (TLC), using precoated Merck silica gel 60 F254 aluminum plates; detection was done with UV and I2. For column chromatography, Merck silica gel (70-230 mesh) was used. Solvents used in the reactions were generally redistilled prior to use and stored over 3A molecular sieves.
Ethyl ester of [1-(1-methyl-6,7- 
[1-(1-Methyl-6,7-methylenedioxy)-isochromanyl]-acetyl hydrazide (6).
An ethanolic solution of ester (5) (1.30 g; 4.65 mmol) in 25 mL of ethanol was heated under stirring until complete dissolution. Then 4.7 mL of 85% hydrazine hydrate was added, and the reaction mixture was stirred at reflux for 3 h. At the end of the reaction (as indicated by TLC analysis) the product (6) was isolated by concentration of the reaction mixture under reduced pressure. Cold water was added and the resulting product (6) was filtered to give The general procedure for preparing 
Benzaldehyde or its derivative (0.57 mmol) was added to a solution of hydrazine derivative (6) (0.15g; 0.57 mmol) in absolute ethanol, in the presence of two drops of hydrochloric acid as a catalyst. The end of the reaction was detected by TLC and the new hydrazones (3a-3g) were isolated by the concentration of the reaction mixture under reduced pressure and the addition of cold water to furnish the desired product as a colored precipitate in an 80% yield ( Table 1) . The E and Z isomers could not be separated, but their 1 H and 13 C assignments could be made from their higher field 2D spectra ( 
[1-(1-Methyl-6,7-methylenedioxy)-isochromanyl]-acetyl arylhydrazone of benzaldeyde (3a-(E),(Z))
[1-(1-Methyl-6,7-methylenedioxy)-isochromanyl]-acetyl arylhydrazone of m-nitrobenzaldehyde (3d-(E),(Z))
[1-(1-Methyl-6,7-methylenedioxy)-isochromanyl] acetylarylhydrazone of p-nitrobenzaldehyde (3e-(E),(Z))
Pharmacology
The analgesic activity was determined in vivo using the abdominal constriction test induced by 0.6% acetic acid (0.1 mL/10 g) in albino mice 24 (ca. 20 g); indomethacin was used as the standard. The solution of acetic acid was administered i.p. and the number of constrictions was registered for 30 min (control). All compounds were administered p.o. in arabic gum (5%) in a dose of 100 mM/kg (0.1 mL/20g) 1 h before the injection of the acetic acid solution. The data were statistically analyzed by the Student t-test, with the significance level set at P < 0.05.
Results and Discussion
The synthesis of new compounds (3a-g) was carried out by exploring the previously described ester (5) 16 synthesized from natural safrole (4) in 80% yield. This synthetic route uses as key step an acid-catalyzed intramolecular alkylation of the 6-position of the aromatic system of the hemiketal intermediate (7), formed in situ from the condensation of homopiperonilic alcohol (8) with ethylacetoacetate (9) , in the presence of the catalytic amount of p-toluenesulfonic acid,as indicated in Scheme 2. The isochromanylacylhydrazide (6), precursor of the desired derivatives (3), was prepared in 85% yield by the conventional treatment of an ethanolic solution of 1-alkyl-1-isochroman ester (5) with 85% hydrazine hydrate, at reflux, to furnish (6) in 85% yield, as outlined in Scheme 3. Finally, the target compounds (3a-g) were prepared in high yield by acidic condensation of (6) with the appropriate aldehydes 20 ( Table 1) . The pattern and choice of the substituent (Ar-W), present in the acylarylhydrazone derivatives (3a-g), was determined by the need to introduce a significant difference in the electronic character in this framework 21 , in order to study the eventual contribution of these structural modifications to bioactivity. Apart from this, the presence of an N-dimethylaminophenyl unit present in (3b) was indicated by the previously described potent analgesic activity detected in compound (2) 11 . 476 Santos et al. J. Braz. Chem. Soc.
Scheme 2. These new derivatives (3a-g) were fully characterized spectroscopically. For instance, in the infrared spectra the presence of a strong absorption at ν 3450 cm -1 is attributed to an -NH group, indicating that the acylhydrazone form predominates over the azo form (Fig. 1) 
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. Careful analysis of hydrogen and carbon-13 nuclear magnetic resonance (NMR) spectra of these derivatives (3a-g) indicated the presence of a diastereomeric mixture at the C=N double bond level, in a 70:30 ratio favoring the (E)-isomer. The analysis of the homonuclear ( shift-correlated spectra confirmed this assumption, especially by the pattern presented by the H-7', C-7', CH2-11, C-12 and NH-12, indicating that the (Z)-isomer resonates at a higher magnetic field than the (E)-isomer ( Table 2) .
These new isochromanylarylacetylhydrazone derivatives (3a-g) were evaluated for their analgesic and anti-inflammatory activities. Unfortunately, these compounds were not effective as anti-inflammatory agents, as observed in the carrageenan-induced rat paw edema test 23 . In this bioassay, only compound 3 g, where W=Br, presented significant activity, inhibiting paw edema in 30.9% in a dose of 100 µmol/kg p.o. The anti-inflammatory test results indicated that the enhanced lipophilicity of the p-bromophenyl template may contribute to the observed activity. The analgesic activity of these compounds was investigated (Table 3) by the inductive abdominal constrictions test in mice 24 , using indomethacin at 30 µmol/kg, p.o., as a standard. The compound possessing the 4-dimethylaminophenyl moiety at the acylhydrazone framework (3c), was the most potent one. In fact, this result seems to indicate, as observed in an other series previously synthesized in our laboratory 25 , that the presence of this functionality could have an important role in analgesic activity (Fig. 2) , probably acting as a hydrogen bond donor in the interaction with the bioreceptor. 
